TG Therapeutics | TGTX - Sales Revenues


TG Therapeutics reported $240.34M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 10.1B 1.48B Jun/2026
Ardelyx USD 94.47M 30.74M Mar/2026
Arrowhead Research USD 75.23M 1.49M Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
Biogen USD 2.74B 490M Jun/2026
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Curis USD 1.14M 1.41M Dec/2025
Gilead Sciences USD 7.8B 800M Jun/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026
Verastem USD 18.67M 1.14M Mar/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026